1.31p-0.06 (-4.31%)20 Jun 2024, 15:39
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Hemogenyx Pharmaceuticals PLC Fundamentals

Company NameHemogenyx Pharmaceuticals PLCLast Updated2024-06-20
Shares in Issue1.342 bnMarket Cap£17.58 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.01EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.4825Debt Equity Ratio0.9482
Asset Equity Ratio2.1956Cash Equity Ratio0.4486
Quick Ratio1.9149Current Ratio3.33
Price To Book Value6.5189ROCE0

Hemogenyx Pharmaceuticals PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Hemogenyx Pharmaceuticals PLC Company Financials

Tangible Assets£3.31 m£3.92 m£797,129.00
Intangible Assets£441,493.00£441,493.00£441,493.00
Total Fixed Assets£3.94 m£4.50 m£1.38 m
Cash & Equivalents£1.25 m£2.53 m£6.84 m
Other Assets000
Total Assets£6.11 m£7.09 m£8.52 m
Creditors within 1 year£652,085.00£748,411.00£352,841.00
Creditors after 1 year£2.67 m£3.10 m0
Other Liabilities000
Total Liabilities£3.32 m£3.85 m£352,841.00
Net assets£2.78 m£3.24 m£8.17 m
Called up share capital£11.76 m£9.80 m£9.80 m
Share Premium£19.94 m£16.81 m£16.81 m
Profit / Loss-£6.70 m-£3.99 m-£5.11 m
Other Equity£2.82 m£3.28 m£8.19 m
Preference & Minorities-£37,723.00-£31,908.00-£24,240.00
Total Capital Employed£2.78 m£3.24 m£8.17 m
Debt Ratio£0.49£0.490
Assets / Equity2.19562.19562.1956
Cash / Equity0.44860.44860.4486
Cash Flow202320222021
Cash from operating activities-£6.11 m-£2.91 m-£2.63 m
Cashflow before financing-£1.66 m-£3.02 m£6.15 m
Increase in Cash-£1.69 m-£3.43 m£5.21 m
Cost of sales£1.68 m£2.20 m£283,647.00
Gross Profit-£1.68 m-£2.20 m-£283,647.00
Operating Profit-£6.47 m-£4.00 m-£2.70 m
Pre-Tax profit-£6.70 m-£3.99 m-£5.11 m

Hemogenyx Pharmaceuticals PLC Company Background

ActivitiesHemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company'stechnologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.
Latest Interim Date28 Sep 2023
Latest Fiscal Year End Date25 Apr 2024

Hemogenyx Pharmaceuticals PLC Directors

2024-04-25Mr. Peter RedmondNon-Executive Director
2017-10-05Mr. Geoffrey Gilbert DartExecutive Director,Chairman
2018-11-05Mr. Lawrence PembleExecutive Director,Chief Operating Officer
2018-04-03Mr. Adrian Richard Thorpe BeestonNon-Executive Director
2024-04-25Dr. Vladislav SandlerExecutive Director,Chief Executive Officer
2024-04-25Ms. Alexis M. Sandler Non-Executive Director
2019-01-04Dr. Robin CampbellNon-Executive Director
2024-04-25Professor Sir. Marc FeldmannNon-Executive Director,Chairman

Hemogenyx Pharmaceuticals PLC Contact Details

Company NameHemogenyx Pharmaceuticals PLC
Address5 Fleet Place, London, EC4M 7RD

Hemogenyx Pharmaceuticals PLC Advisors

Financial AdviserPeterhouse Corporate Finance Ltd
Phone+44 2074690930
Fax+44 2072209798
StockbrokerOptiva Securities Ltd
Phone+44 2031371902
SolicitorCharles Russell Speechlys LLP
Phone+44 2072035000
BankMetro Bank Plc
AuditorPKF Littlejohn
Phone+44 2075162200
Fax+44 2075162400
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
Financial PR AdviserCamarco
Phone+44 02037574980